Corteva (NYSE:CTVA) Price Target Raised to $86.00 at Wolfe Research

Corteva (NYSE:CTVA) had its target price increased by Wolfe Research from $81.00 to $86.00 in a report released on Thursday morning,MarketScreener reports. Wolfe Research currently has an outperform rating on the stock.

CTVA has been the subject of a number of other reports. Royal Bank Of Canada boosted their price objective on Corteva from $80.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday. Wall Street Zen upgraded Corteva from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. JPMorgan Chase & Co. cut Corteva from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $75.00 to $77.00 in a research note on Thursday. UBS Group reduced their target price on shares of Corteva from $85.00 to $81.00 and set a “buy” rating for the company in a research note on Thursday, October 30th. Finally, Mizuho raised their price target on shares of Corteva from $78.00 to $80.00 and gave the company an “outperform” rating in a research report on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $82.37.

Corteva Stock Up 1.6%

Shares of CTVA traded up $1.14 during trading hours on Thursday, reaching $73.61. The stock had a trading volume of 90,869 shares, compared to its average volume of 3,922,674. The firm has a 50-day simple moving average of $68.72 and a 200 day simple moving average of $68.43. Corteva has a 12 month low of $53.40 and a 12 month high of $77.41. The company has a current ratio of 1.43, a quick ratio of 1.07 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $49.74 billion, a price-to-earnings ratio of 46.45, a P/E/G ratio of 1.86 and a beta of 0.75.

Corteva (NYSE:CTVA) last released its quarterly earnings data on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.22. The firm had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. Corteva had a net margin of 6.29% and a return on equity of 9.06%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period last year, the firm earned $0.32 earnings per share. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. Equities research analysts predict that Corteva will post 2.96 earnings per share for the current fiscal year.

Corteva Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 16th. Stockholders of record on Monday, March 2nd will be issued a $0.18 dividend. This represents a $0.72 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Monday, March 2nd. Corteva’s dividend payout ratio is presently 45.57%.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Fideuram Intesa Sanpaolo Private Banking S.P.A. bought a new position in shares of Corteva during the 4th quarter valued at $9,561,000. PNC Financial Services Group Inc. raised its position in Corteva by 1.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 673,135 shares of the company’s stock valued at $45,120,000 after purchasing an additional 10,165 shares during the last quarter. Larson Financial Group LLC boosted its holdings in Corteva by 2.8% in the fourth quarter. Larson Financial Group LLC now owns 34,492 shares of the company’s stock valued at $2,312,000 after acquiring an additional 942 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in shares of Corteva by 7.6% during the 4th quarter. Handelsbanken Fonder AB now owns 402,845 shares of the company’s stock valued at $27,003,000 after purchasing an additional 28,517 shares in the last quarter. Finally, ProShare Advisors LLC grew its holdings in shares of Corteva by 10.8% during the 4th quarter. ProShare Advisors LLC now owns 146,416 shares of the company’s stock worth $9,814,000 after acquiring an additional 14,257 shares during the period. Hedge funds and other institutional investors own 81.54% of the company’s stock.

More Corteva News

Here are the key news stories impacting Corteva this week:

• Positive Sentiment: Multiple banks raised price targets and kept bullish ratings, increasing buy-side momentum. Deutsche Bank raised its target to $90 and maintained a “buy” rating (largest upside call among the recent raises). Deutsche Bank raises target to $90
• Positive Sentiment: Wolfe Research bumped its target to $86 and reiterated an “outperform” rating, signaling a roughly mid‑teens upside vs. current levels. Wolfe Research raises target to $86
• Positive Sentiment: RBC increased its price target to $89 and kept an “outperform” rating, adding to the cluster of analysts signaling ~20%+ upside potential. RBC raises target to $89
• Neutral Sentiment: Aggregate analyst view remains mildly constructive — broker consensus is a “Moderate Buy,” reinforcing the message of multiple target hikes but not an across‑the‑board upgrade. Consensus Moderate Buy
• Neutral Sentiment: Coverage pieces note the company’s bull case could change depending on outcomes from a Bayer settlement and licensing shifts — a potential catalyst but with uncertain timing and impact. Bull case and Bayer settlement
• Negative Sentiment: JPMorgan cut Corteva from “overweight” to “neutral” (though they slightly raised their PT to $77), flagging valuation and limited near‑term upside — this downgrade tempers some of the recent bullish analyst noise. JPMorgan downgrade
• Negative Sentiment: Corteva’s Q4 results missed revenue estimates (seasonal timing and lower crop protection/seed demand) and the company reported a wider loss, which pushed shares lower after hours — this is the primary near‑term operational weakness investors are weighing. Q4 revenue miss and after‑hours drop

About Corteva

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.